Research Analysts’ Recent Ratings Changes for Definium Therapeutics (DFTX)

A number of research firms have changed their ratings and price targets for Definium Therapeutics (NASDAQ: DFTX):

• 8/18/2026 – Definium Therapeutics is now covered by Bank of America Corporation. They set a “buy” rating and a $75.00 price target on the stock.
• 8/14/2026 – Definium Therapeutics was given a new $55.00 price target by Maxim Group. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics was given a new $64.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by JonesTrading from $74.00 to $90.00. They now have a “buy” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Royal Bank Of Canada from $57.00 to $66.00. They now have an “outperform” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Wells Fargo & Company from $68.00 to $72.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Definium Therapeutics had its price target raised by Robert W. Baird from $57.00 to $75.00. They now have an “outperform” rating on the stock.
• 8/12/2026 – Definium Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $70.00 price target on the stock.
• 8/12/2026 – Definium Therapeutics had its price target raised by Needham & Company LLC from $50.00 to $66.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/7/2026 – Definium Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $75.00 price target on the stock, up from $73.00.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 7/27/2026 – Definium Therapeutics is now covered by Wells Fargo & Company. They set an “overweight” rating and a $68.00 price target on the stock.
• 7/26/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/24/2026 – Definium Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $73.00 price target on the stock, up from $48.00.
• 7/18/2026 – Definium Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Definium Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – Definium Therapeutics had its price target raised by Stifel Nicolaus from $30.00 to $60.00. They now have a “buy” rating on the stock.
• 7/4/2026 – Definium Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/30/2026 – Definium Therapeutics was given a new $58.00 price target by Canaccord Genuity Group Inc.. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, insider Mark Sullivan sold 13,008 shares of Definium Therapeutics stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the sale, the insider owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. The trade was a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the transaction, the chief executive officer directly owned 1,098,246 shares of the company’s stock, valued at $49,454,017.38. The trade was a 2.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 48,096 shares of company stock valued at $2,165,763. Company insiders own 2.40% of the company’s stock.

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.